Dexcom Inc
NASDAQ:DXCM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Dexcom Inc
NASDAQ:DXCM
|
US |
|
B
|
Borgwarner Inc
LSE:0HOU
|
US |
Intrinsic Value
The intrinsic value of Dexcom Inc (DXCM) under the Base Case is 77.38 USD per share.
Compared with the current market price of 84.23 USD, the stock appears
Overvalued by 8% .
The intrinsic value is calculated using the DCF method. The model assumes Dexcom's net margin rises from 18% last year to 23% by 2036. If its margin stayed at its five-year average of 14%, the estimate would be about $65. The value of the years after 2036 is based on revenue, so margins affect only the forecast years.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Dexcom Does
Dexcom makes continuous glucose monitoring systems for people with diabetes. Its core product is a small wearable sensor that tracks glucose levels through the day and sends readings to a smartphone, receiver, or insulin pump, so users can manage blood sugar without repeated finger sticks. The company also sells the software and connected apps that display trends and alerts.
- Headquarters
- United States of America US
- Employees
- 11 000
- IPO date
- Apr 14, 2005
Dexcom has a narrow economic moat
Patents covering Dexcom’s glucose-sensing technology make its products harder to copy. Connections to compatible insulin pumps also give some patients a practical reason to stay, because changing sensors can mean changing how their diabetes equipment works together. These protections limit competition without shutting out established rivals such as Abbott.
Read the full moat analysis
Revenue & Expenses Breakdown
Dexcom Inc
Earnings Waterfall
Dexcom Inc
The intrinsic value for Dexcom Inc (DXCM) under the Base Case is 77.38 USD.
Compared with the current market price of 84.23 USD, the stock appears Overvalued by 8% .